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Mr. Chairman, Senator Grassley, and Members of the Committee, I am pleased to be
here with you today.  This morning I will discuss the Congressional Budget Office’s
(CBO’s) projections of Medicare spending for 2003 through 2012 and compare them
with those of the Administration.  I will then summarize CBO’s estimates of the cost
of the President’s budgetary proposals for Medicare.  Last, I will describe CBO’s new
projections of prescription drug spending for the Medicare population and outline some
general approaches for providing prescription drug coverage through Medicare.
THE IMPACT OF CHANGING DEMOGRAPHICS
ON SPENDING FOR MEDICARE
Before describing CBO’s projections, I would first like to underscore that the long-
range picture of federal spending that I described to you last year remains unchanged.
Looking at Medicare’s near-term situation and proposals to increase payments to
providers or to add a prescription drug benefit within the context of the program’s long-
term financial pressures can provide a beneficial perspective. 
The aging of the baby boomers has dramatic fiscal implications for Medicare (see
Figure 1 on page 16).  If the nation spent the same fraction of gross domestic product
(GDP) on each Medicare beneficiary in 2030 as it does today—a proposition reflecting
only the increased number of beneficiaries in the program at that point—spending for
Medicare would grow from today’s 2.3 percent share of GDP to 4.5 percent by 2030.
However, the fiscal implications of the baby boomers’ aging are compounded by the
fact that health care costs measured per beneficiary routinely grow significantly faster
than does the economy measured on a per capita basis.  As a result, if current law
remains unchanged, CBO expects that spending for Medicare will climb to 5.4 percent
of GDP by 2030.
Also projected to rise is spending for the “big three” entitlement programs—Social
Security, Medicare, and Medicaid—taken as a whole.  Between now and 2030, such
spending as a share of GDP will virtually double.  Expenditures for those programs will
grow from 7.8 percent of GDP to 14.7 percent by 2030 (see Figure 2).
That increase in spending of almost 7 percentage points will occur under current law.
Proposals to increase payments to providers of services in the Medicare program or to
expand the program’s benefits through prescription drug coverage would exacerbate
the long-term budgetary pressures projected for the next several decades.  As this
Committee knows, paying for those increased costs will require either dramatic
reductions in spending, sizable increases in taxes, or large-scale borrowing.
1. In addition, the costs of administering the program, which are funded annually by appropriations, will amount to
an estimated $3.6 billion in 2002.
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Within the context of that longer-term perspective, I will now turn to CBO’s
projections of Medicare spending for the next 10 years, which we have just completed
updating as part of our analysis of the President’s budgetary proposals.  CBO’s new
baseline projections of Medicare spending over the 2003-2012 period are lower by
about $80 billion relative to its estimates in January.  The revisions, which are mainly
the result of new information, leave CBO’s overall estimate for the period about $225
billion higher than the Administration’s.  That amounts to a difference of about 7
percent over the 10-year projection period, but CBO’s and the Administration’s
estimates differ by only 4 percent over the five-year budget window.  And regardless
of their differences, both CBO’s and the Administration’s baseline projections reflect
underlying forces that are likely to continue to exert upward pressure on spending in
the Medicare program.
CBO’S PROJECTIONS OF MEDICARE SPENDING
UNDER CURRENT LAW
CBO projects that gross mandatory outlays for Medicare will total $248 billion in 2002
(or 2.4 percent of GDP) and $3.6 trillion over the 2003-2012 period, reaching 2.8
percent of GDP by 2012 (see Table 1).  After deducting projected premium payments
by beneficiaries of $26 billion in 2002 and about $400 billion over the 10 years, CBO
estimates that net mandatory spending for Medicare will total $223 billion in 2002 and
$3.2 trillion from 2003 through 2012 (see the table below).1  All of CBO’s projections
incorporate the assumption that current law remains unchanged.
Projected Growth of Spending and Payments to
Medicare Service Providers
CBO projects that net mandatory spending for Medicare will grow at a rate of 7.1
percent in 2002 and at an annual average rate of 6.6 percent over the 2003-2012 period.
Those rates take into account a shift in the timing of some payments, which is described
below.
3SUMMARY OF CBO’S MARCH 2002 BASELINE PROJECTIONS
OF MANDATORY MEDICARE OUTLAYS (By fiscal year)
Average Annual
Rate of Growth,
Billions of Dollars 2003-2012
2002 2003-2012 (Percent)
Gross Mandatory Outlays 248 3,590 6.9
Premiums  -26  -413 8.4
Net Mandatory Outlays
Unadjusted 223 3,177 6.7
Adjusted for timing shiftsa 226 3,177 6.6
SOURCE:  Congressional Budget Office.
a. Outlays are adjusted to eliminate the effect of accelerating payments to group plans from October to September in some years.
In recent years, the annual growth rate of spending for Medicare has varied
considerably.  Growth averaged 1.2 percent annually during the 1997-2000 period but
then shot up to 10.3 percent in 2001.  That jump stemmed in part from a provision of
the Balanced Budget Act of 1997 (BBA) that accelerated $3 billion in payments to
group plans (mainly Medicare+Choice) from October to September 2001—or from
fiscal year 2002 to fiscal year 2001.  (Another reason for the resumption of significant
growth in 2001 was that by that time, Medicare had absorbed the substantial changes
in payment rules enacted in the BBA.  Other sources of growth were increases in
payment rates and other changes enacted in the Balanced Budget Refinement Act and
the Benefits Improvement and Protection Act.)  Adjusted for the shift in group-plan
payments, the underlying rate of growth in 2001 was 8.7 percent.
Over the next decade, CBO expects several factors to play a major role in the
program’s spending growth.  Those factors include rising enrollment in Medicare,
automatic increases in payment rates in the fee-for-service sector (to adjust rates for the
rising prices of inputs), and changes in the use of Medicare’s services, which will lead
to more services being furnished per enrollee and to a shift in the mix of services
toward those that are higher-priced and (often) more technologically advanced.  In part
offsetting the effects of those spending components will be smaller updates
(adjustments) to the rates paid to Medicare+Choice plans relative to updates to rates in
the fee-for-service sector.  (Overall, CBO expects that spending for Medicare+ Choice
2. For its January projection, CBO assumed that, overall, payment rates for Medicare+Choice (M+C) plans would
grow at the same rate as spending per capita in the fee-for-service sector.  CBO now estimates that M+C payment
rates in all areas will increase by 2 percent in both 2003 and 2004.  Rates in areas subject to a “floor” amount will
increase by more than 2 percent in 2005 and grow with fee-for-service spending in subsequent years, but all other
rates will increase by 2 percent annually until they reach the level of the floor amount or a 50/50 blend of local and
national rates.  (CBO estimates that the proportion of payments made at floor amounts or at 50/50-blend rates will
increase from about 40 percent in 2005 to 95 percent by 2012.)
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and other group plans will decline through 2006 and then grow slowly, returning to its
2001 level by 2012.)
The growth rates of Medicare’s payments for services vary for particular types of
Medicare service providers.  Payments to hospitals for inpatient services and payments
to physicians, which account for two-thirds of outlays, are the slowest-growing
components of spending in the fee-for-service sector, respectively averaging 6.3
percent and 5.4 percent annually in CBO’s baseline projections through 2012.  By
contrast, the rates of increase in payments for other services—for example, those
provided by home health agencies and nonphysician professionals—are projected to
average 9 percent to 16 percent annually.
Changes in CBO’s Baseline Projections Since January
As I mentioned earlier, CBO’s March baseline projection of $3.2 trillion in net
mandatory spending for Medicare over the next 10 years is about $80 billion—or 2.5
percent—lower than the projection of that spending made in January.  Three factors
account for that overall revision:
! A reduction of about $30 billion in projections of payments to Medicare+
Choice plans.  That change reflects the Administration’s announcement in
January of preliminary Medicare+Choice payment rates for 2003 and updates
to CBO’s projections of enrollment in those plans.2  (CBO now projects that the
percentage of Medicare enrollees in Medicare+Choice plans will decline from
15 percent in 2001 to 8 percent by 2012.) 
! A reduction of about $35 billion in projections of payments for hospital
outpatient services.  That change reflects the Administration’s announcement
implementing lower “pass-through” payments for certain new technologies used
in delivering services, coupled with an analysis of updated data on the cost of
Medicare’s “buying down” (contributing more to) coinsurance paid by
beneficiaries for hospital outpatient services.
5! A reduction of another $15 billion in projected spending to better reflect the
changing age distribution of Medicare beneficiaries, an improved method for
constructing price indexes for projecting updates to payment rates, and the
effects of revised projections of outlays on the premiums paid by beneficiaries.
COMPARISON OF CBO’S AND THE ADMINISTRATION’S
MEDICARE PROJECTIONS
The Administration’s baseline estimate of $3.0 trillion in net mandatory spending for
Medicare over the 2003-2012 period is about $225 billion, or 7 percent, lower than
CBO’s projection for the same period (see Figure 3).  For 2003, the difference between
the two projections amounts to 1.8 percent; over the 2003-2007 period, the difference
is 4.2 percent.  The Administration projects that net mandatory spending for Medicare
will grow at an average annual rate of 5.4 percent through 2012, in comparison with
CBO’s projected (and adjusted) rate of 6.6 percent (see Table 2).  The Administra-
tion’s projection shows spending growing more slowly than that 10-year average
through 2006 (average annual growth of 4.0 percent) and more quickly after 2006
(average annual growth of 6.4 percent).  The pattern of growth in CBO’s projection is
similar.  Rates are relatively low through 2006 (averaging 5.7 percent a year), and
higher after 2006 (averaging 7.7 percent a year).  The factors that contribute to the
difference between the two projections—which, in the context of Medicare spending,
is not large—are discussed in Appendix A.
CBO’S ESTIMATES OF THE COSTS OF THE PRESIDENT’S
BUDGETARY PROPOSALS FOR MEDICARE
The President’s budgetary proposals for Medicare include two major components:  a
Medicare-funded program that would give states the option of providing prescription
drug benefits administered by their Medicaid programs to Medicare beneficiaries
whose income is below 150 percent of the poverty level, and an allowance of $116
billion over the 2006-2012 period for a “Medicare Modernization” program.  As a
temporary measure, pending implementation of the modernization program, the
President proposes to increase the payment rates for Medicare+Choice plans during the
2003-2005 period.  The President’s budget also includes three provisions to reduce
Medicare spending—first, by establishing competitive bidding for some durable
medical equipment; second, by adding new options for supplemental insurance
(medigap); and third, by strengthening requirements for insurers that process Medicare
claims to report beneficiaries for whom Medicare might be the secondary payer.
  
3. CBO assumes that the components of the President’s budgetary proposals need not sum to $190 billion over the
10-year period.  As a result, CBO’s lower estimate, relative to the Administration’s, of the President’s proposal for
a prescription drug benefit for low-income beneficiaries does not mean that additional funds would be available
for Medicare modernization.
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CBO estimates that the President’s proposals would increase spending by $1.6 billion
in 2003 and $169 billion over the 2003-2012 period.  In contrast, the Administration
estimates that those provisions would increase spending by $190 billion over 10 years.3
Nearly all of the difference between the two numbers lies in estimates of the cost of
offering coverage for prescription drugs to low-income Medicare beneficiaries.  The
difference arises largely because of differing assumptions about how many
beneficiaries would participate in the benefit and what, on average, those benefits
would cost.  
Medicare Modernization and Medicare+Choice
The Administration has stated that it will work with the Congress to develop legislation
to modernize Medicare, including providing coverage for prescription drugs and
preventive health care services and protecting beneficiaries from catastrophic costs.
In its analysis of the President’s budgetary proposals, CBO used the Administration’s
estimate of $116 billion for the Medicare Modernization proposal because that proposal
lacks sufficient details for CBO to develop an independent estimate.
Offering beneficiaries a choice among multiple health plans is an important element of
a modernized Medicare, according to the Administration.  To encourage health plans
to participate in Medicare, the President’s budget contains a proposal that, beginning
in 2003, would increase the level of payments to Medicare+Choice plans and establish
incentive payments to encourage new or existing plans to expand into new geographic
markets.  CBO estimates that those provisions would increase spending by $3 billion
over the 2003-2005 period, which contrasts with the Administration’s estimate of
nearly $4 billion. The Administration (and CBO) did not estimate the cost of the
provisions beyond 2005 because the budgetary effects in subsequent years are included
in the $116 billion allowance for modernizing Medicare. 
7Prescription Drug Benefits for Low-Income Medicare Beneficiaries
The President’s budget includes a proposal that would give states the option of
providing prescription drug benefits to certain low-income Medicare beneficiaries
whose income is below 150 percent of the poverty level.  The benefits would be
administered through the beneficiaries’ state Medicaid programs, which Medicare
would reimburse for the costs of the program.  States would have considerable
flexibility in determining the drug benefits that would be provided, the amounts that
beneficiaries would pay in the form of premiums or copayments, and any restrictions
on eligibility for individuals with assets.  Beneficiaries covered by the proposal would
receive only prescription drug benefits; they would not be eligible for the full package
of benefits under Medicaid.  The federal government would reimburse the states at the
usual matching rate for Medicaid (57 percent, on average) for spending on beneficiaries
whose income falls below the poverty level.  The matching rate would be 90 percent
for spending on beneficiaries between 100 percent and 150 percent of the poverty level.
CBO estimates that this proposal would increase spending by a total of $57 billion over
the 2003-2012 period, whereas the Administration projects a cost of $77 billion over
the same span.  Differing assumptions about rates of participation and per capita costs
(see Appendix B for more information) are the main reason that CBO’s estimate differs
from that of the Administration. 
Provisions to Reduce Spending by the Medicare Program
The President’s budget also contains several provisions that would reduce Medicare
spending over the 2003-2012 period, including:
! A proposal for a nationwide competitive-bidding system that would encourage
companies to sell durable medical equipment at prices lower than those
Medicare currently pays.  Both CBO and the Administration estimate that this
proposal would decrease Medicare spending by approximately $4 billion over
the 10-year period.
! A proposal to add two private medigap plans with high deductibles to the 10
standard medigap plans already available to beneficiaries.  Enrollees in the new
plans, which would provide catastrophic coverage, would probably use fewer
Medicare-covered services because the plans would not cover as much of
beneficiaries’ initial cost sharing as many current medigap policies cover.  Both
8CBO and the Administration estimate that this proposal would reduce Medicare
spending by approximately $1 billion over the 2003-2012 period.
! A proposal requiring that insurers and group health plans periodically report to
Medicare those beneficiaries for whom Medicare could be the secondary payer.
Both CBO and the Administration estimate that this proposal would decrease
Medicare spending by approximately $1 billion over the 10-year period.
PROVIDING COVERAGE FOR PRESCRIPTION DRUGS TO MEDICARE
BENEFICIARIES
CBO has analyzed data on beneficiaries’ current spending for prescription drugs and
developed preliminary projections of spending for outpatient drugs not currently
covered by Medicare.  Several approaches to providing drug coverage may be
suggested by those data.  However, in considering ways to provide a prescription drug
benefit, a key factor to keep in mind is the implication of CBO’s projections for the
Medicare program.
Beneficiaries’ Current Spending for Prescription Drugs
CBO’s analysis of Medicare’s Current Beneficiary Survey suggests that in 1999, one-
quarter of the Medicare population had no prescription drug coverage, although 75
percent had coverage for at least part of the year.  On average, the share of their drug
expenditures that Medicare beneficiaries paid out of pocket was nearly 40 percent—the
same share paid out of pocket by the U.S. population as a whole (see Figure 4).  But
because Medicare beneficiaries are generally elderly or disabled, they are more likely
to have chronic health conditions and to use more prescription drugs than the general
population:  consequently, nearly 90 percent filled at least one prescription in 1999.
Medicare beneficiaries made up almost 15 percent of the population that year, yet they
accounted for about 40 percent of the more than $100 billion spent on outpatient
prescription drugs in the United States. 
Those factors suggest that growth in spending for prescription drugs has a larger
financial impact on the Medicare population than on other groups in the population.
Nevertheless, overall statistics mask a wide variety of personal circumstances.  In 1999,
for example, nearly 30 percent of Medicare beneficiaries obtained coverage for
prescription drugs through employer-sponsored retiree benefits, and another 16 percent
had coverage through state Medicaid programs.  Although the extent of coverage by
4. CBO estimates that about 14 percent of Medicare beneficiaries obtained drug coverage through health maintenance
organizations, primarily Medicare+Choice plans.  And over 4 percent of Medicare beneficiaries received some drug
coverage through other public programs, such as state pharmacy assistance programs or benefits through the
Department of Veterans Affairs.  All estimates of coverage are based on CBO’s analysis of the Medicare Current
Beneficiary Survey Cost and Use files for 1999.
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employers and state Medicaid programs varies considerably, in general, those kinds of
plans typically include relatively low deductibles and small copayments.  About 11
percent of beneficiaries had drug coverage through individually purchased medigap
policies in 1999, but that coverage tends to be much less generous, with higher
deductibles, coinsurance of 50 percent, and annual limits on benefits.4  In 1999, 25
percent of Medicare beneficiaries had no drug coverage at all, paying out of pocket for
all of their spending on drugs.
CBO’s Projection of Prescription Drug Spending for the Medicare Population
Last May, CBO estimated that spending by or on behalf of Medicare enrollees for
outpatient prescription drugs not covered by Medicare would total $1.5 trillion between
2002 and 2011 (see Table 3).  This year, CBO’s preliminary projection for the same
period is $1.6 trillion, or about 8 percent higher.
However, CBO’s estimate of spending for prescription drugs over the current 10-year
projection period of 2003 through 2012 is roughly $1.8 trillion—or 21 percent higher
than last year’s projection for the 2002-2011 period.  Nearly two-thirds of that increase
simply reflects the shift in the so-called projection window, which effectively
substitutes a high-cost year (2012) for a relatively low-cost one (2002).  The remaining
growth reflects changes to CBO’s estimates of how much, on average, is spent on a
Medicare beneficiary to purchase prescription drugs both today and in the future.
Note that the projections I have just described are preliminary in nature.  In developing
them, CBO used information from its March baseline projections of Medicare
spending, which were released last week.  We have been working quickly to prepare
estimates of prescription drug spending because we understand the Committee’s need
to develop legislative proposals in a timely manner.  However, I would emphasize that
CBO is still reviewing its projections and their underlying assumptions. 
For 2003, CBO’s preliminary projections suggest that, on average, a Medicare
beneficiary will incur more than $2,400 in spending for prescription drugs used on an
outpatient basis (see Table 4).  The median value, a more representative measure of
what most people spend, will be nearly $1,500 per person that year.
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Even without a Medicare prescription drug benefit, CBO expects average spending for
prescription drugs to grow rapidly—at an average annual rate of about 10 percent per
beneficiary—over the 2003-2012 period.  That rate is considerably faster than the rate
of growth projected for the combined costs of Medicare’s Hospital Insurance and
Supplementary Medical Insurance programs (Parts A and B) and for the nation’s
economy.  However, that rate is also significantly lower than recent rates of growth: the
Centers for Medicare and Medicaid Services estimates that spending per person for
prescription drugs, averaged among everyone in the United States, grew by nearly 14
percent annually between 1995 and 2000 and peaked at more than 18 percent in 1999.
Some of the slowdown in growth is associated with brand-name drugs whose patents
will expire between now and the middle of the decade; some of it arises as well from
a decline in the number of new drugs in development. 
Implications of CBO’s Estimates for the Costs of a Medicare
Prescription Drug Benefit
To get a sense of what a proposal for prescription drug coverage might cost, consider
a benefit that covered purchases of drugs only after an enrollee spent more than a
deductible amount of $3,000.  CBO’s preliminary estimates suggest that in 2005, about
a third of Medicare beneficiaries will spend $3,000 or more purchasing prescription
drugs.  Spending at or above that level would equal $52 billion, or about 41 percent,
of a total of $128 billion in prescription drug expenditures that year (see Table 5).  If
the Medicare program subsidized 50 percent of beneficiaries’ prescription drug
spending at or above the $3,000 level, its costs for that benefit would total roughly $26
billion that year, with enrollees paying the remaining $26 billion through premiums,
cost sharing, and payments by other insurers.  (Enrollees and their non-Medicare
insurers would also be responsible for covering the first $76 billion in prescription drug
spending—that is, the costs of their purchases before reaching the $3,000 deductible
amount.)
Although that example indicates the magnitude of Medicare’s spending for such a
benefit, it ignores some potentially large costs, such as subsidies to cover the federal
share of premiums and cost sharing for low-income enrollees as well as the costs of
creating and administering the new benefit.  Moreover, most proposals for prescription
drug coverage have had much more complicated structures—with lower deductibles
to encourage broader enrollment and often caps on benefits to constrain costs to the
Medicare program—than does the structure described in this example of a traditional
insurance arrangement.
5. For example, if a proposal called for a deductible of $250 and a stop-loss amount of $5,000 beginning in 2004,
CBO would use those same values of $250 and $5,000 but assume that the benefit would start in 2005. 
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My presentation of CBO’s estimates of prescription drug spending at today’s hearing
does not signal that CBO is fully prepared to score new proposals immediately. We are
now “benchmarking” our models, in part by updating our estimates for some of the
options developed in the 106th Congress.  As part of that process, CBO is reviewing
assumptions that were incorporated in earlier cost estimates in the light of more recent
data and developments in the market for prescription drugs. We expect to be ready to
provide briefings on the updated estimates and assumptions within a month.
The changes to CBO’s baseline projections—to incorporate higher drug spending per
capita and a new high-cost year in the projection window—imply that the price tags on
proposals for a prescription drug benefit will be bigger today than they were last year.
Exactly how much more costly is difficult to say, but recent experience may offer some
guidance.  Last year, CBO’s baseline projection for total drug spending over the 2002-
2011 period was 33 percent higher than the preceding projection as a result of the shift
in the budget window and increases in estimates of prescription drug spending per
person.  Although that growth of 33 percent affected all proposals, the increase in costs
for any specific option depended on the structure of its benefit package.  For some of
the proposals that CBO updated last year, the increase in costs of the Medicare drug
benefit was considerably higher than the percentage increase in the baseline projection.
In updating its estimate of a proposal, CBO uses the same nominal values for
deductibles, benefit limits, and stop-loss amounts (the cap on beneficiaries’ out-of-
pocket spending) that it used in estimating costs when the proposal was introduced.5
Keeping those nominal features the same when drug spending is growing makes a bill’s
deductibles and stop-loss amounts relatively more generous.  In contrast, for proposals
that cap Medicare’s drug benefit at a fixed dollar amount, keeping the same value for
that limit would make the proposal relatively less generous as drug spending grew.
Under the nominal-dollar approach, some proposals introduced in the past would now
be considerably more generous than they were when introduced—which means that the
federal government would subsidize more of enrollees’ prescription drug spending.
For some proposals, a higher share of covered benefits would also translate into higher
rates of enrollment, which would lead to even larger costs for the Medicare program.
6. One study of prescription drug use among an insured senior population found that the top 10 categories of therapies
ranked by number of prescriptions per person per year were for conditions that were primarily chronic in nature.
Those therapies represented 55 percent of all claims.  See Emily Cox and Catherine Roe, Prescription Use Among
a Commercially Insured Senior Population, 1998 (St. Louis:  Express Scripts, Inc., May 2001).
7. A study of the drug spending of people age 65 or older found that those with the highest costs tended to use drugs
from multiple therapeutic classes, suggesting the presence of several chronic conditions.  See Cindy Thomas, Grant
Ritter, and Stanley Wallack, “Growth in Prescription Drug Spending Among Insured Elders,” Health Affairs, vol.
20, no. 5 (September/October 2001).
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Although this year’s updated estimates of similar proposals will undoubtedly be higher
than last year’s estimates, they will not necessarily be 21 percent higher.  Indeed,
CBO’s updated cost estimates could reflect higher rates of growth than the growth in
baseline spending, depending on the structure of the proposals’ benefits.
Patterns of Spending for Drugs and Other Health Services
The distribution of drug spending for Medicare beneficiaries is skewed:  although
nearly 90 percent of Medicare beneficiaries use some prescription drugs, the bulk of
the population’s drug spending is concentrated among a smaller group of individuals.
For example, CBO projects that by 2005—the first year in which Medicare could
probably begin to implement a new benefit—17 percent of enrollees will account for
55 percent of total drug spending by the Medicare population.  Moreover, the annual
spending of an individual enrollee among that 17 percent is likely to exceed $5,000.
About 25 percent of Medicare beneficiaries are expected to have spending of $500 or
less.  Spending by those beneficiaries would make up just 1 percent of total prescription
drug spending. 
Yet even with that degree of asymmetry, spending for Medicare beneficiaries’
outpatient prescription drugs is less concentrated than is spending for benefits that are
already covered by the Medicare program.  For example, the 10 percent of beneficiaries
who have the highest spending for prescription drugs account for 40 percent of all
outpatient prescription drug spending, whereas the 10 percent of beneficiaries who
have the highest spending for the combination of services covered by Parts A and B of
the program account for 65 percent of all Medicare spending.
Another characteristic of beneficiaries’ prescription drug spending is that much of it
is related to chronic health conditions, which often call for long-term drug therapies.6
One implication of the association between chronic conditions and drug spending is
that people with the very highest spending for drugs are likely to continue to have high
spending in the future.7
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In comparison with spending for prescription drugs, spending for some services now
covered by Medicare is much more variable for individuals over time—particularly
expenditures for services related to hospitalizations and stays in other facilities.  Even
though many hospital admissions are ultimately related to an individual’s chronic
conditions, anticipating the timing of any one person’s use of inpatient services is
difficult. Nevertheless, there may be a certain proportion of Medicare beneficiaries—
probably those with chronic conditions—who have high expenditures and who account
for a large share of Medicare spending consistently from year to year.
More analysis is needed to understand the relationship between the use of outpatient
drugs and spending for Medicare benefits.  That relationship may vary by disease, by
type of benefit, or by patient characteristic.  However, for some beneficiaries who are
very ill, one would expect spending for all types of health care services to be high.  For
others, the relationship may not be as clear. 
CBO is analyzing the distribution of costs for Medicare services among beneficiaries
in an effort to identify trends in spending and the characteristics associated with high
levels of expenditures.  What is now known is that, not surprisingly, Medicare
beneficiaries who generate high costs for the program are very sick people, and a
significant fraction of them die during or soon after the spell of illness that prompts
those expenditures.  But over half of the beneficiaries with high levels of expenditures
survive, and some of them continue to generate high costs in succeeding years. Some
of the goals of CBO’s analysis are to identify beneficiaries with high costs for currently
covered Medicare services, determine whether there is a percentage of the population
that consistently generates high costs, distinguish the clinical characteristics of that
population, and assess whether high-cost individuals can be identified.
Providing a Medicare Drug Benefit
Thus far, the debate over providing a prescription drug benefit under Medicare has
focused on two general approaches:  offering coverage to all Medicare beneficiaries or
targeting coverage toward people with low income. However, other approaches are also
available, although some have received less attention during the debate.  Some
policymakers advocate expanding Medicare benefits as part of a broader reform of the
Medicare program. The organization and financing of health care have changed
substantially since Medicare was established, and many private and public plans
typically offer broader and more flexible packages of benefits.  Medicaid has also
moved toward offering broader coverage and flexibility to states in the structuring and
administration of their programs.
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An alternative approach is to target a Medicare drug benefit toward enrollees with
specific clinical conditions rather than particular economic circumstances.  For
example, an integrated package of Medicare benefits could be developed that included
a strategy for coordinating care and prescription drugs to help manage patients with
certain diseases or chronic conditions.  Along those lines, the Centers for Medicare and
Medicaid Services recently announced a three-year demonstration project mandated by
the Congress under which several disease-management organizations will develop
approaches for managing patients with advanced-stage congestive heart failure,
diabetes, and coronary heart disease.  The announcement of the initiative noted that the
demonstration will include coverage of prescription drugs for participating
beneficiaries.
CONCLUSION
CBO’s March baseline projection of $3.2 trillion in net mandatory spending for
Medicare over the 2003-2012 period is about $80 billion, or 2.5 percent, lower than the
projection released in January.  Nevertheless, CBO’s current projection and that of the
Administration reflect underlying forces that will lead to faster growth in Medicare
spending than in the economy as a whole.  Some of those forces are the increases in
payments to providers, which are linked automatically to changes in the prices of
inputs; the rising volume of services being provided and changes in the mix of services
toward those that are more technologically advanced and, in general, more costly; and
increases in enrollment in the Medicare program. 
Those factors contribute to the upward pressure on spending that is inherent in the
Medicare program’s structure under current law, and proposals to increase payments
for certain providers would intensify that pressure.  But the effects of those forces are
overwhelmed by the dramatic growth of spending projected to begin at the end of this
decade, as the baby-boom generation starts to become eligible for Medicare.
CBO’s preliminary estimates suggest that spending for outpatient prescription drugs
for the Medicare population will total $1.8 trillion between 2003 and 2012.  That
amount is 21 percent larger than last year’s 10-year total, primarily because of the
addition of a high-cost year (2012) and the loss of a low-cost one (2002).  If the
Medicare program subsidized a significant portion of beneficiaries’ total drug
expenditures, federal spending would jump.  Moreover, CBO projects that over the
2003-2012 period, per-person spending for prescription drugs will grow at rates of
more than 10 percent annually.  Thus, without other changes to Medicare’s benefits or
15
the way in which the program is financed, adding a comprehensive prescription drug
benefit would add significantly to the program’s future budgetary pressures. 
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spending.  For further details, see Congressional Budget Office, The Budget and Economic Outlook:  Fiscal Years 2003-2012
(January 2002), Chapter 6.
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TABLE 1. CBO’S MARCH 2002 BASELINE PROJECTIONS OF MANDATORY OUTLAYS FOR
MEDICARE, 2002-2012 (In billions of dollars)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Total,
2003-
2012
Part A: Hospital Insurance
Fee-for-service program
Hospital inpatient care 102 108 115 122 130 138 147 156 166 176 188 1,445
Hospice 4 4 4 5 5 6 6 6 7 7 8 59
Skilled nursing facilities 14 14 15 17 19 21 23 25 27 30 33 224
Home health services     6     6     6     7     9   10   12   13   15   17   19    115
Subtotal 126 132 141 151 162 174 187 201 215 231 248 1,843
Group plansa   18   18   17   18   15   17   17   18   18   21   19    177
Total, Part A Benefits 144 150 158 169 177 191 204 218 234 252 267 2,020
Part B: Supplementary Medical
Insurance
Fee-for-service program
Physician fee schedule 43 44 44 46 49 52 56 60 64 68 72 556
Other professional and
outpatient ancillary servicesb 19 21 23 26 29 32 35 38 42 46 50 341
Other facilitiesc 21 22 24 27 29 32 36 39 43 46 51 350
Home health services   6   7     8   10   11   13   15   17   20   23   26    149
Subtotal 88 94 100 108 118 129 142 155 168 183 199 1,396
Group plansa   15   16   15   16   13   15   15   16   17   19   17    159
Total, Part B Benefits 103 109 115 124 131 144 157 171 185 202 216 1,555
All Medicare Benefits 247 259 273 293 309 335 361 389 419 454 483 3,575
Other Mandatory Outlays     2     2     2     1     2     2     1     2     2     1     2      15
Gross Mandatory Outlays 248 261 274 294 310 336 363 391 420 456 484 3,590
Premiums -26 -28 -30 -32 -35 -39 -42 -46 -50 -54 -58    -413
Net Mandatory Outlays 223 233 245 262 275 298 321 345 371 402 426 3,177
Memorandum:
All Home Health Agencies 11 12 14 17 20 23 27 31 35 40 45 264
All Group Plans 33 34 31 33 28 32 32 34 35 41 36 336
All Fee-for Service Programs 214 225 241 260 280 303 329 355 384 414 447 3,238
Net Outlays as a Percentage of GDP 2.2 2.1 2.1 2.2 2.1 2.2 2.3 2.3 2.4 2.4 2.5 n.a.
SOURCE: Congressional Budget Office.
NOTE:   Numbers may not add up to totals because of rounding.
a. Group plans include Medicare+Choice plans, plans paid on a cost basis, health care prepayment plans, and some demonstrations.  Nearly
all enrollment and spending is in Medicare+Choice plans.
b. Includes durable medical equipment, independent and physician in-office laboratory services, ambulance services, and other services paid
by carriers.
c. Includes hospital outpatient services, laboratory services in hospital outpatient departments, rural health clinic services, outpatient dialysis,
and other services paid by fiscal intermediaries.  Also includes payments to skilled nursing facilities for services covered under Part B.
19
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
0
100
200
300
400
500
Billions of Dollars
CBO January
Administration February
CBO March
2003
2003-
2007
2003-
2012
In Billions of Dollars
   CBO January Baseline 235 1,338 3,255
   CBO March Baseline 233 1,313 3,177
   Administration 229 1,258 2,951
Percentage Difference,
CBO March Baseline
Minus Administration 1.8 4.2 7.0
FIGURE 3. CBO’S AND THE ADMINISTRATION’S BASELINE PROJECTIONS OF
NET MANDATORY OUTLAYS FOR MEDICARE, 2002-2012
SOURCE: Congressional Budget Office.
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TABLE 2. COMPARISON OF CBO’S AND THE ADMINISTRATION’S BASELINE PROJECTIONS OF
NET MANDATORY OUTLAYS FOR MEDICARE, 2002-2012
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Total,
2003-
2012
Net Mandatory Outlays
(Billions of dollars)
CBO 223 233 245 262 275 298 321 345 371 402 426 3,177
Administration 223 229 237 252 260 279 297 317 337 363 378 2,951
Difference (CBO minus
Administration) 0 4 7 10 15 19 23 28 34 39 48 226
Annual Percentage
Change in Spending
CBO 4.0 4.7 4.9 7.3 4.8 8.3 7.6 7.6 7.5 8.3 6.1 6.6a
Administration 4.0 2.8 3.6 6.4 3.2 7.3 6.4 6.6 6.4 7.8 4.2 5.4b
SOURCE: Congressional Budget Office.
NOTE:   Numbers may not add up to totals because of rounding.
a. Average annual rate adjusted to eliminate the effect of accelerating payments to group plans from October to September in some years.
b. Average annual rate.
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FIGURE 4.  DISTRIBUTION OF DRUG SPENDING FOR MEDICARE BENEFICIARIES,
BY PAYER, IN 1999
SOURCE: Congressional Budget Office.
NOTE: HMOs = health maintenance organizations.
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TABLE 3. COMPARISON OF  CBO’S MARCH 2002 AND MAY 2001 BASELINE
PROJECTIONS OF PRESCRIPTION DRUG SPENDING BY THE
MEDICARE POPULATION (In billions of dollars)
Calendar
Year
March 2002
Estimate
May 2001
Estimate
2002 87 81
2003 100 92
2004 113 104
2005 128 117
2006 143 131
2007 160 148
2008 179 166
2009 200 186
2010 222 208
2011 248 236
2012 278 n.a.
Total
2002-2011 1,581 1,467
2003-2012 1,773 n.a.
Memorandum:
Percentage Increase in Total Spending, March 2002 Estimates Over May 2001 Estimates, 
for 10 Years Ending in 2011 7.8
Percentage Increase in Total Spending, 10 Years Ending in 2012 (using March 2002 estimates)
Over 10 Years Ending in 2011 (using May 2001 estimates) 20.8
SOURCE: Congressional Budget Office.
NOTES: Numbers may not add up to totals because of rounding.
n.a. = not applicable.
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TABLE 4. CBO’S BASELINE PROJECTIONS OF PRESCRIPTION DRUG
SPENDING AND MEDICARE BENEFITS PER ENROLLEE,
CALENDAR YEARS 2003-2012
Average Annual
Spending per Enrollee (Dollars) Percentage Change, 
2003 2012 2003-2012
Mean Drug Spendinga 2,440 5,820 10.1
Median Drug Spendingb 1,460 3,490 10.2
Medicare Benefitsc 6,585 10,631 5.5
Memorandum:
Gross Domestic Product per Capita 37,900 55,800 4.4
SOURCE: Congressional Budget Office.
a. Total spending per enrollee on outpatient prescription drugs not currently covered under Medicare, regardless of payer.  Numbers based
on CBO’s March 2002 projections.
b. The median reflects the point at which half of all beneficiaries are projected to spend more than that amount and half are projected to spend
less.  Based on CBO’s March 2002 projections.
c. Medicare benefits per enrollee under the Hospital Insurance and Supplementary Medical Insurance programs.  Based on CBO’s March 2002
baseline projections.
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TABLE 5. PROJECTED SPENDING ON PRESCRIPTION DRUGS
BY OR FOR MEDICARE ENROLLEES IN CALENDAR YEAR 2005
Spending Level
per Enrollee
(Dollars)
Spending At or 
Above the Level
(Billions of dollars)
Share of Enrollees
with Spending Above
the Level (Percent)
Share of Total
Drug Spending Above the
Level (Percent)
0 128.1 89.8 100.0
500 110.0 75.1 85.9
1,000 94.7 64.4 73.9
2,000 70.2 47.4 54.8
3,000 52.4 33.7 40.9
4,000 39.7 24.5 31.0
5,000 30.5 17.3 23.8
6,000 24.1 12.4 18.8
7,000 19.3 9.3 15.1
8,000 15.8 6.9 12.3
9,000 13.1 5.5 10.2
10,000 10.9 4.3 8.5
SOURCE: Congressional Budget Office.
NOTES: Numbers are based on CBO’s March 2002 projections.
Total Medicare enrollment for 2005 is projected to be 41.9 million people.
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APPENDIX A: SOURCES OF VARIATION BETWEEN CBO’S AND
THE ADMINISTRATION’S MEDICARE BASELINES
The Congressional Budget Office’s (CBO’s) and the Administration’s projections of
Medicare spending differ by about $225 billion over the 2003-2012 period.  That
difference stems from divergences in the assumptions underlying those estimates.
Differences Arising from Economic Assumptions
About $40 billion of the 10-year difference between CBO’s and the Administration’s
estimates results from differing economic projections.  Payment rates for most services
are adjusted, or updated, each year to reflect changes in the prices of inputs.  In general,
CBO projects that those updates to payment rates will be 0.1 or 0.2 percentage points
higher than the Administration’s projected updates.
Differences Resulting from Assumptions About Administrative Actions
Another $10 billion to $20 billion of the 10-year difference stems from possible
administrative actions that the Administration’s baseline takes account of but that CBO’s
does not.  The Administration’s baseline incorporates the assumption that the payment
method for outpatient prescription drugs covered under the Medicare program will
change in 2003.  However, the Administration has not yet put forward a specific proposal
for changing the payment rules.  As a result, CBO’s projections incorporate the
assumption that Medicare continues to use the existing payment method.
Differences Stemming from Technical Assumptions
The remaining difference of about $175 billion over 10 years reflects different technical
assumptions about enrollment in Medicare+Choice plans and in the rate of increase in the
volume and mix of services provided to beneficiaries in the fee-for-service sector.  A
clear comparison of CBO’s and the Administration’s baselines by payment category is
difficult, because the two groups of estimates reflect very different assumptions about the
proportion of beneficiaries who will participate in Medicare+Choice plans.
Assumptions About Medicare+Choice.  The Administration projects that the propor-
tion of beneficiaries enrolled in Medicare+Choice plans will remain fairly stable (in the
range of 14 percent to 15 percent) over the coming decade, whereas CBO projects a sharp
decline in that share (to 8 percent) by 2012.  The Administration’s assumption that a
relatively large share of Medicare enrollees will remain in Medicare+Choice plans while
the plans’ payment rates are growing much more slowly than rates in the fee-for-service
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sector may contribute significantly to the differences between CBO’s and the Administra-
tion’s baseline projections of Medicare spending. 
Assumptions About Growth Stemming from the Volume and Mix of Services in the
Fee-for-Service Sector.  The projections of both CBO and the Administration
incorporate the assumption that spending per capita for services in the fee-for-service
sector of Medicare will grow at a faster rate than will the adjustments to payment rates
for changes in input prices.  In general, however, CBO projects larger increases in per
capita spending as a result of changes in the volume and mix of services than the
Administration does.
Those assumptions about spending increases differ the most for the areas of skilled
nursing services, hospital outpatient services, and home health services.  The payment
systems in all three settings have changed substantially in the past few years, and whether
and how the volume and mix of services will change under the new systems is uncertain.
Both CBO and the Administration assume that increases in the volume and changes in
the mix of those services will contribute less to growth in spending under current law
than they contributed under the payment systems that existed before the Balanced Budget
Act of 1997 was enacted.  CBO estimates that the contributions to growth made by
volume and mix changes will steadily decline over the coming decade as follows:
! For skilled nursing services, dropping from about 7 percentage points a year in the
next few years to 4.5 percentage points by 2012;
! For hospital outpatient services and other payments to facilities for services
covered under Part B of Medicare, falling from about 5.3 percentage points
annually to 3.8 percentage points; and
! For home health services, declining from 12.5 percentage points to 7 percentage
points a year.
The Administration appears to make a similar assumption about the steadily lessening
effect of changes in the volume and mix of services—although it projects a more rapid
decline  than does CBO—for skilled nursing services and hospital outpatient services.
Compared with CBO’s assumption about the effects of volume and mix changes for home
health services, however, the Administration’s assumption seems to reflect more-rapid
increases in the effects of volume and mix changes for home health services through 2005
or 2006 and a more rapid decline in subsequent years. 
CBO and the Administration make very similar assumptions about the effects of volume
and mix changes in relation to the sustainable growth rate (SGR) system of payment for
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services on the physician fee schedule and in relation to payments to hospitals for
inpatient services.  
The SGR system automatically adjusts payment rates for services on the schedule to
compensate for changes in the volume and mix of services.  Therefore, the differences
between CBO’s projections of payments under the physician fee schedule and the
Administration’s projections are almost entirely attributable to economic factors and to
differences in the projected number of beneficiaries in the fee-for-service sector.
Likewise, both CBO and the Administration assume that changes in the mix and volume
of services contribute about 1 percentage point to annual increases in payments to
hospitals for inpatient services—1 percentage point, that is, above the growth resulting
from increases in enrollment and adjustments for inflation.

29
APPENDIX B: CBO’S ASSUMPTIONS FOR ITS ESTIMATE OF THE
ADMINISTRATION’S PRESCRIPTION DRUG PROPOSAL
In developing estimates of the costs of the President’s recent proposal for prescription
drug coverage, the Administration and the Congressional Budget Office (CBO) used
different assumptions for three factors:  which states would participate by offering
coverage, how many eligible beneficiaries would enroll for the benefit, and the level of
spending per enrollee.
Participation by States
CBO anticipated that certain states would be more likely than others to provide coverage
for prescription drugs under this proposal.  First, states that have pharmacy assistance
programs (23 at last count) would be more likely to participate because the proposal
would allow them to receive federal matching funds for those programs, which are now
entirely state-funded.  Second, states whose Medicaid programs already cover all aged
and disabled individuals below the poverty level would be more likely to participate than
states that do not provide such coverage.  For the states that already covered those
low-income people, expanded coverage for prescription drugs would qualify for the
higher federal matching rate of 90 percent and thus require relatively little additional state
spending.  At least 15 states fall into that category, and another four have eligibility limits
that are just below the poverty level. In contrast, states with less generous Medicaid
programs would have to expand eligibility significantly—and on average pay 43 percent
of the resulting costs—before they would receive the 90 percent federal match.
Of the remaining states, CBO expects that a portion would participate and that they would
be less likely than other states to expand coverage fully to 150 percent of the poverty
level.
CBO assumed that about 65 percent of the population eligible for the proposed benefit
would reside in participating states.  The Administration assumed that about 70 percent
of the eligible population would come from those states.
Participation by Beneficiaries
In developing its estimate, CBO also made an assumption about the level of participation
of Medicare beneficiaries in states that decided to offer prescription drug coverage under
the proposal.  CBO assumed that almost 60 percent of eligible Medicare beneficiaries
would ultimately participate, on the basis of experience with Medicaid and other
low-income programs as well as the extent of employer-sponsored coverage among the
eligible population.  Thus, CBO estimated, the total number of participants in the 
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program would gradually rise from about 900,000 in 2003 to 2.4 million by 2007;
participants would constitute about 6 percent of all Medicare beneficiaries and 18 percent
of beneficiaries with income below 150 percent of the poverty level.  By comparison, the
Administration assumed that about 70 percent of eligible beneficiaries would participate.
Those differing assumptions are the primary reason that CBO’s estimate is lower than the
Administration’s.
Per Capita Costs
Finally, CBO assumed that the generosity of the prescription drug benefits offered under
the proposal would vary from state to state, ranging from the benefits provided by
pharmacy assistance programs to those provided under employer-sponsored coverage.
CBO also anticipated that the prescription drug benefits typically offered by the states
would be less generous than those provided in existing state Medicaid programs.  The
Administration’s estimate incorporated the assumption that the drug benefits provided
under the proposal would equal average drug spending for the overall Medicare
population, as calculated from the accounts maintained by the Centers for Medicare and
Medicaid Services.
Charts Presented at the Hearing
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Growth Since 1967 in Medicare Spending
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